A Phase 2 interventional study of Votoplam in Huntington Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 24 sites in 10 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Huntington Disease with a site in Germany — 7 open to participants now, 9 under way, 3 of them phase 3. Huntington Disease · Germany.
Among the 44 studies in Huntington Disease with a site in Germany, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 in phase 2, and was the 39th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →7 of the 44 studies in Huntington Disease with a site in Germany are open now. Recruiting first, the newest first:
Prilenia · Sites in Germany, United States, Belgium and 9 more countries
Ages 23–65
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in Germany, United States, Argentina and 7 more countries
Ages 25+
Alnylam Pharmaceuticals · Sites in Germany, Canada, United Kingdom
Ages 25–70
Vico Therapeutics B. V. · Sites in Germany, Denmark, France and 3 more countries
Ages 25–60
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 7
First in 2004; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 95 across the 37 interventional studies, 574 across the 7 observational. Of the 33 that completed or were terminated, 21 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 5 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Huntington Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02855476University College, LondonHDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Huntington Disease with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
Participants who completed the Treatment Period in the parent Phase 2a Study PTC518-CNS-002-HD (NCT05358717), fulfilled the enrollment criteria, and chose to enroll in this extension study will undergo baseline evaluations and be assessed for 54 additional months.
All participants will receive active votoplam in this extension study. Participants who received votoplam in the parent Study PTC518-CNS-002-HD will continue at the same dose level they received in that study in a blinded fashion (5, 10 milligrams [mg]). Participants who received placebo in the parent Study PTC518-CNS-002-HD will be allocated to a votoplam dose level according to the same dosing group in which they were previously randomized (5, 10 mg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Participants will receive Votoplam 5 mg tablets once daily orally for 48 months.
Drug: Votoplam
Participants will receive votoplam 10 mg tablets once daily orally for 48 months.
Drug: Votoplam
Votoplam will be administered per dose and schedule specified in the arm.
Also known as: HTT227 / PTC518
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline up to Month 54
Blood Total Huntingtin Protein (tHTT) Levels
Time frame: Baseline up to Month 52
Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 48
Time frame: Baseline, Month 48
Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 48
Time frame: Baseline, Month 48
Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) Levels
Time frame: Baseline up to Month 48
Blood mHTT Protein Levels
Time frame: Baseline up to Month 52
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Jul 2029, 70 months after the start.
Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's planned 70 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Votoplam